Transition of late-stage effector T cells to CD27(+) CD28(+) tumor-reactive effector memory T cells in humans after adoptive cell transfer therapy

In humans, the pathways of memory T-cell differentiation remain poorly defined. Recently, adoptive cell transfer (ACT) of tumor-reactive T lymphocytes to metastatic melanoma patients after nonmyeloablative chemotherapy has resulted in persistence of functional, tumor-reactive lymphocytes, regression of disease, and induction of melanocyte-directed autoimmunity in some responding patients. In the current study, longitudinal phenotypic analysis was performed on melanoma antigen-specific CD8(+) T cells during their transition from in vitro cultured effector cells to long-term persistent memory cells following ACT to 6 responding patients. Tumor-reactive T cells used for therapy were generally late-stage effector cells with a CD27(Lo) CD28(Lo) CD45RA(-) CD62 ligand(-) (CD62L(-)) CC chemokine receptor 7(-) (CCR7(-)) interieukin-7 receptor alpha(Lo) (IL-7Ralpha(Lo)) phenotype. After transfer, rapid up-regulation and continued expression of IL-7Ralpha in vivo suggested an important role for IL-7R in immediate and long-term T-cell survival. Although the tumor antigen-specific T-cell population contracted between 1 and 4 weeks after transfer, stable numbers of CD27(+) CD28(+) tumor-reactive T cells were maintained, demonstrating their contribution to the development of long-term, melanoma-reactive memory CD8+ T cells in vivo. At 2 months after transfer, melanoma-reactive T cells persisted at high levels and displayed an effector memory phenotype, including a CD27(+) CD28(+) CD62L(-) CCR7(-) profile, which may explain in part their ability to mediate tumor destruction. (C) 2005 by The American Society of Hematology.